Skip to main content

Vyvanse FDA Approval History

FDA Approved: Yes (First approved February 23, 2007)
Brand name: Vyvanse
Generic name: lisdexamfetamine dimesylate
Dosage form: Capsules
Company: Shire plc
Treatment for: ADHD

Vyvanse (lisdexamfetamine dimesylate) is an amphetamine derivative prodrug administered once-daily for the treatment of attention deficit hyperactivity disorder (ADHD) and binge-eating disorder.

Development timeline for Vyvanse

DateArticle
Jan 30, 2015Approval FDA Expands Uses of Vyvanse to Treat Binge-Eating Disorder
Feb  7, 2012Approval Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD
Nov 15, 2010Approval FDA Approves Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
Jun  1, 2009Approval FDA Approves Labeling Change for Vyvanse (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
Apr 23, 2008Approval FDA Approves Vyvanse (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Jan  3, 2008Approval FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment Vyvanse (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
Feb 26, 2007Approval Shire Receives FDA Approval of Vyvanse for ADHD
Dec 21, 2006New River Pharmaceuticals and Shire Receive Approvable Letter for Vyvanse
Oct  6, 2006FDA Issues Approvable Letter for NRP104 (lisdexamfetamine dimesylate) for the Treatment of ADHD
Jan 27, 2006New River Pharmaceuticals Announces NRP104 NDA Accepted for Review
Dec  7, 2005Shire Announces New River Pharmaceuticals Filing of NRP104

See also

Vyvanse (lisdexamfetamine dimesylate) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer